ASCO 2025 | Real-world impact of bevacizumab with pembrolizumab in cervical cancer
Alberto Farolfi, MD, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, gives an overview of a real-world analysis assessing the effectiveness of pembrolizumab in metastatic cervical cancer based on platinum type and use of bevacizumab. Findings suggest comparable survival outcomes between cisplatin- and carboplatin-based regimens when combined with pembrolizumab. However, addition of bevacizumab was associated with improved overall survival, with no increased risk of fistulae or pulmonary embolism, though a higher incidence of bowel perforation was observed. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
